{
  "id": "26da7e4f52035175",
  "title": "Precision Medicine Portfolio Update : Illuccix China Phase 3 Study , TLX101 - CDx and TLX250 - CDx FDA Resubmissions",
  "description": "20251222T000000Z",
  "content": "",
  "source": "singaporestar.com",
  "source_url": "http://www.singaporestar.com/news/278768125/precision-medicine-portfolio-update-illuccix-china-phase-3-study-tlx101-cdx-and-tlx250-cdx-fda-resubmissions",
  "published_at": "20251222T000000Z",
  "fetched_at": "2025-12-22T00:24:16.044990+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "china",
    "fda"
  ],
  "location": "Singapore",
  "raw_data": {
    "url": "http://www.singaporestar.com/news/278768125/precision-medicine-portfolio-update-illuccix-china-phase-3-study-tlx101-cdx-and-tlx250-cdx-fda-resubmissions",
    "url_mobile": "",
    "title": "Precision Medicine Portfolio Update : Illuccix China Phase 3 Study , TLX101 - CDx and TLX250 - CDx FDA Resubmissions",
    "seendate": "20251222T000000Z",
    "socialimage": "",
    "domain": "singaporestar.com",
    "language": "English",
    "sourcecountry": "Singapore"
  }
}